PanTera and Belgoprocess have signed a long-term agreement for the purification of radium, a key raw material for the future large-scale production of actinium-225 (Ac-225). This radioisotope shows great promise for targeted cancer therapy. Belgoprocess has also recently commenced the opening of a new series of thorium-229 capsules for PanTera, further strengthening the availability of Ac-225 for clinical applications.
These developments not only underscore the complementarity of both organizations but also confirm the strategic role of the nuclear ecosystem in the Mol-Dessel region. By pooling their expertise, Belgoprocess and PanTera contribute to a robust European supply chain for medical radioisotopes and to the development of innovative treatments for cancer patients worldwide.
“"Team Pantera Belgoprocess: from left to right: Mieke Roos, Wim Van Laer (CEO Belgoprocess), Carlot Valgaeren, Thomas Huys, Marnix Braeckeveldt, Matthias Sprangers, Jasper Mermans, Sven Van den Berghe (CEO PanTera)."




